Table 4.
Renin-angiotensin drugs subgroups consumption between AD and control patients.
| Variable | AD | Control |
|---|---|---|
| Angiotensin-converting enzyme inhibitors prescription (n, (%)) | 40 (17.94) | 5 (8.77) |
| Angiotensin-converting enzyme inhibitors prescription duration (months, median (IQR)) | 42 (11, 106) | 19 (1, 48) |
| Plain angiotensin-converting enzyme inhibitors prescription prescription (n, (%)) | 30 (13.45) | 1 (1.75) |
| Combinations of angiotensin-converting enzyme inhibitors prescription prescription (n, (%)) | 10 (4.48%) | 4 (7.02%) |
| Angiotensin-converting enzyme inhibitors prescription without medical records of angiotensin II receptor blockers prescription (n, (%)) | 33 (14.8%) | 4 (7.02%) |
| Angiotensin II receptor blockers prescription (n, (%)) | 50 (22.42%) | 20 (35.09%) |
| Angiotensin II receptor blockers duration (months, median (IQR)) | 83 (56.75, 118.75) | 69 (39, 95) |
| Plain angiotensin II receptor blockers (n, (%)) | 21 (9.42%) | 7 (12.28%) |
| Combinations of angiotensin II receptor blockers (n, (%)) | 29 (13%) | 12 (21.05%) |
| Angiotensin II receptor blockers prescription without medical records of angiotensin-converting enzyme inhibitors prescription (n, (%)) | 43 (19.28) | 18 (31.58) |
IQR = Interquartile range; n = number of patients.